By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BerGenBio AS 

Thormohlensgt 51, 5006

  Bergen    Norway
Phone: 47-535-01-564 Fax: n/a



Company News
BerGenBio AS: New BGB324 Study Points To Novel Mechanism To Enhance Immunotherapy Efficacy 9/26/2016 11:18:42 AM
ASCO2016: BerGenBio AS Reports First-In-Patient Phase 1 Data For BGB324 In Patients With Myeloid Malignancies At The 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting 6/7/2016 10:38:37 AM
BerGenBio AS Presents New Data Demonstrating That BGB324 Enhances Checkpoint Inhibitor Blockade 4/18/2016 9:06:40 AM
BerGenBio AS Bags $25 Million 3/18/2016 6:07:29 AM
BerGenBio AS Release: BGB324 Enhances Immune Checkpoint Inhibitor Efficacy In Preclinical Cancer Models 9/21/2015 9:10:59 AM
BerGenBio AS Awarded 2015 Nordic Stars Award 9/14/2015 11:43:57 AM
AMRA, BerGenBio AS And Nexstim Receive Nordic Stars 2015 Awards At NLSDays In Stockholm 9/14/2015 11:42:49 AM
BerGenBio AS Awarded 2015 Nordic Stars Award 9/11/2015 10:16:24 AM
BerGenBio AS Appoints Non-Executive Directors 9/1/2015 6:51:44 AM
BerGenBio AS Initiates NSCLC Clinical Trial With BGB324 In Combination With erlotinib 6/10/2015 6:39:15 AM